Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

04-02 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	€0.000800	0.00%	4,046,200
22/10/26	€0.000800	0.00%	349,555
21/10/26	€0.000800	+33.33%	350,356
20/10/26	€0.000600	-40.00%	17,321,410
19/10/26	€0.001000	+25.00%	146,690

Real-time Euronext Bruxelles

More quotes

Market Closed - Euronext Bruxelles 16:55:00 23/10/2026 BST			5-day change	1st Jan Change
0.000800 ^EUR	0.00%		0.00%	-88.89%

09-29	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT

Market Cap	113K 126K 104K 94.26K 176K 11.97M 179K 1.25M 496K 6.27M 473K 463K 19.77M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.12M 12.46M 10.28M 9.31M 17.42M 1.18B 17.71M 124M 48.96M 620M 46.75M 45.76M 1.95B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	68.41%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Bruxelles	OXUR	Real-time
CBOE	THR	Real-time
Börse Stuttgart	TG40	Delayed
Deutsche Boerse AG	TG40	End-of-day quote
CBOE	0G99	Real-time
Boerse Muenchen	TG40	Real-time

09-29	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-29	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-29	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-02	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
14/10/25	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
01/10/25	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/08/25	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
22/07/25	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT

Oxurion NV Share Price

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation: Oxurion NV

Chart: Oxurion NV

Latest news: Oxurion NV

Press Releases: Oxurion NV

News in other languages: Oxurion NV

Quotes and Performance

Price Extremes

Managers and Directors: Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

10-15	Oxurion Nv : Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC	AT
10-12	Oxurion Nv : Oxurion Receives Transparency Notifications from Market Wizards B.V. and Atlas Special Opportunities II LLC	AT
10-09	Oxurion Nv : Oxurion Receives Transparency Notification from Market Wizards B.V.	AT
09-30	Oxurion : Interim Financial Report — Half-year results as of 30 June 2026 (EN)	PU
09-30	Oxurion Nv : Oxurion Publishes First Half 2026 Results	AT

10-15	Oxurion Nv : Oxurion ontvangt transparantiekennisgevingen van Market Wizards B.V. en van Atlas Special Opportunities II LLC
10-12	Oxurion Nv : Oxurion ontvangt transparantiekennisgevingen van Market Wizards B.V. en van Atlas Special Opportunities II LLC
10-09	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Market Wizards B.V.
10-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
09-30	Oxurion : Tussentijdse halfjaarresultaten 30 juni 2026 (NL)

Current month	-42.86%
1 month	-50.00%
3 months	-66.67%
6 months	-80.00%
Current year	-88.89%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		18
5 years	0		23,700
10 years	0		104,600

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	27/12/2023
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	27/12/2023
Samuel Darcheville SEC	Corporate Secretary	-	27/12/2023

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	27/12/2023
James Hartmann BRD	Director/Board Member	60	27/12/2023
Charles Paris de Bollardire CHM	Chairman	-	27/12/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/03/22	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
11/03/22	Midelco NV	Buy	Company	1,180	0.0030%
17/11/21	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	0.00%	0.00%	-94.67%	-99.99%	126K
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	+0.25%	+2.17%	+35.09%	+131.80%	38.31B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%

	2024	2025
Net sales	3K 3.36K 2.77K 2.51K 4.7K 319K 4.78K 33.35K 13.2K 167K 12.61K 12.34K 527K	555K 622K 513K 465K 869K 59M 884K 6.17M 2.44M 30.91M 2.33M 2.28M 97.46M
Net income	119K 133K 110K 99.62K 186K 12.65M 189K 1.32M 524K 6.63M 500K 489K 20.9M	-3.73M -4.17M -3.44M -3.12M -5.84M -396M -5.94M -41.44M -16.41M -208M -15.67M -15.33M -655M
Net Debt	10.87M 12.17M 10.04M 9.1M 17.03M 1.16B 17.31M 121M 47.85M 606M 45.69M 44.72M 1.91B	11.01M 12.33M 10.17M 9.22M 17.25M 1.17B 17.53M 122M 48.47M 613M 46.28M 45.29M 1.93B